['DRUGS THAT AFFECT RENAL FUNCTION', 'CAUTION\xc2\xa0SHOULD\xc2\xa0BE\xc2\xa0EXERCISED\xc2\xa0WHEN\xc2\xa0COMBINING\xc2\xa0DIGOXIN\xc2\xa0WITH\xc2\xa0ANY DRUG THAT MAY CAUSE SIGNIFICANT DETERIORATION IN RENAL FUNCTION (E.G., ACE INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, NONSTEROIDAL ANTI-INFLAMMATORY DRUGS [NSAIDS], COX-2 INHIBITORS) SINCE A DECLINE IN GLOMERULAR FILTRATION OR TUBULAR SECRETION MAY IMPAIR THE EXCRETION OF DIGOXIN.', 'ANTIARRTHYMICS', 'DOFETILIDE', 'CONCOMITANT ADMINISTRATION WITH DIGOXIN WAS ASSOCIATED WITH A HIGHER RATE OF TORSADES DE POINTES', '', 'SOTALOL', 'PROARRHYTHMIC EVENTS WERE MORE COMMON IN PATIENTS RECEIVING SOTALOL AND DIGOXIN THAN ON EITHER ALONE; IT IS NOT CLEAR WHETHER THIS REPRESENTS AN INTERACTION OR IS RELATED TO THE PRESENCE OF CHF, A KNOWN RISK FACTOR FOR PROARRHYTHMIA, IN PATIENTS RECEIVING DIGOXIN.', '', 'DRONEDARONE', 'SUDDEN DEATH WAS MORE COMMON IN PATIENTS RECEIVING DIGOXIN WITH DRONEDARONE THAN ON EITHER ALONE; IT IS NOT CLEAR WHETHER THIS REPRESENTS AN INTERACTION OR IS RELATED TO THE PRESENCE OF ADVANCED HEART DISEASE, A KNOWN RISK FACTOR FOR SUDDEN DEATH IN PATIENTS RECEIVING DIGOXIN.', 'PARATHYROID HORMONE ANALOG', 'TERIPARATIDE', 'SPORADIC CASE REPORTS HAVE SUGGESTED THAT HYPERCALCEMIA MAY PREDISPOSE PATIENTS TO DIGITALIS TOXICITY. TERIPARATIDE TRANSIENTLY INCREASES SERUM CALCIUM.', 'THYROID SUPPLEMENT', 'THYROID', 'TREATMENT OF HYPOTHYROIDISM IN PATIENTS TAKING DIGOXIN MAY INCREASE THE DOSE REQUIREMENTS OF DIGOXIN.', 'SYMPATHOMIMETICS', 'EPINEPHRINE NOREPINEPHRINE DOPAMINE', 'CAN INCREASE THE RISK OF CARDIAC ARRHYTHMIAS', 'NEUROMUSCULAR\xc2\xa0BLOCKING\xc2\xa0AGENTS', 'SUCCINYLCHOLINE', 'MAY CAUSE SUDDEN EXTRUSION OF POTASSIUM FROM MUSCLE CELLS CAUSING ARRHYTHMIAS IN PATIENTS TAKING DIGOXIN.', 'SUPPLEMENTS', 'CALCIUM', 'IF ADMINISTERED RAPIDLY BY INTRAVENOUS ROUTE, CAN PRODUCE SERIOUS ARRHYTHMIAS IN DIGITALIZED PATIENTS.', 'BETA-ADRENERGIC BLOCKERS AND CALCIUM CHANNEL BLOCKERS', '', 'ADDITIVE EFFECTS ON AV NODE CONDUCTION CAN RESULT IN BRADYCARDIA AND ADVANCED OR COMPLETE HEART BLOCK.'] RIFAMPIN, ST.\xc2\xa0JOHN\xe2\x80\x99S WORT, SUCRALFATE, SULFASALAZINE', 'MEASURE SERUM DIGOXIN CONCENTRATIONS BEFORE INITIATING CONCOMITANT DRUGS. CONTINUE MONITORING AND INCREASE DIGOXIN DOSE BY APPROXIMATELY 20 % TO 40 % AS NECESSARY.', 'NO SIGNIFICANT DIGOXIN EXPOSURE CHANGES', 'PLEASE\xc2\xa0REFER\xc2\xa0TO\xc2\xa0SECTION\xc2\xa012\xc2\xa0FOR\xc2\xa0A\xc2\xa0COMPLETE\xc2\xa0LIST\xc2\xa0OF\xc2\xa0DRUGS\xc2\xa0WHICH WERE STUDIES BUT REPORTED NO SIGNIFICANT CHANGES ON DIGOXIN EXPOSURE.', 'NO\xc2\xa0ADDITIONAL\xc2\xa0ACTIONS\xc2\xa0ARE\xc2\xa0REQUIRED.', 'NA \xe2\x80\x93 NOT AVAILABLE/REPORTED']